PROVIDENCE, R.I., July 31, 2026
Nabsys 2.0, LLC has entered into a multi-year research collaboration with Indiana University School of Medicine to advance Electronic Genome Mapping (EGM) applications for hematologic malignancies, initially focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The collaboration will evaluate Nabsys’ OhmX™ Platform, a research-use-only technology designed to analyze ultra-long DNA molecules and provide high-resolution information on structural variants and copy number changes. Kevin T.A. Booth, Ph.D., FACMG, Assistant Professor in the Department of Medical and Molecular Genetics at Indiana University School of Medicine and Clinical Laboratory Director at Indiana University Genetic Testing Laboratories, will evaluate the platform to support development and assessment of EGM applications. While AML and MDS represent the initial areas of investigation, the collaboration could eventually expand into additional hematologic malignancies and constitutional disorders.
Electronic Genome Mapping Targets Structural Variation
Structural genomic variation plays an important role in many hematologic malignancies, but comprehensive characterization of these abnormalities can require multiple complementary technologies. Fluorescence in situ hybridization, or FISH, examines a limited number of genomic regions, while conventional karyotyping provides a genome-wide view of structural information but at comparatively low resolution. Through the collaboration, Nabsys and Indiana University will investigate whether Electronic Genome Mapping can complement existing cytogenetic research workflows and provide additional insight into structural abnormalities associated with AML, MDS and potentially other diseases. Nabsys’ OhmX Platform uses proprietary electronic detection technology to analyze ultra-long DNA molecules. By replacing complex optical detection systems with precision electronics, the platform is designed to deliver high-resolution structural variant and copy number analysis through a more compact approach. The technology integrates precision electronics, nanofluidics and computational biology to generate genome-wide structural information at the single-molecule level.
OhmX Platform Evaluated in AML and MDS Research
The research program will initially examine applications of OhmX Electronic Genome Mapping in AML and MDS, two hematologic diseases where genomic abnormalities can play an important role in understanding disease biology. According to the collaborators, structural variation remains both scientifically important and technically challenging within cancer genomics. The research will therefore assess where EGM could provide complementary information alongside established cytogenetic methods. The collaboration combines Indiana University’s expertise in cytogenetics, molecular genetics and genomic medicine with Nabsys’ electronic genome mapping technology. The work will also help Nabsys further develop research applications addressing challenges associated with structural variant analysis. Importantly, OhmX is currently designated for research use only and is commercially available to laboratories worldwide; the announcement does not describe the platform as an approved clinical diagnostic test. The multi-year research collaboration is therefore focused on evaluating and developing potential genomic research applications rather than introducing a new clinical diagnostic indication.
Advertisement
Nabsys Expands Cancer Genomics Research for OhmX
The collaboration comes as Nabsys continues to expand research around Electronic Genome Mapping for hematologic malignancies and genomic structural variation. The company also plans to participate in the Cancer Genomics Consortium Annual Meeting, August 1–5, 2026, in Houston, Texas, where it will present new research related to EGM applications in hematologic malignancies. Through an oral presentation and three scientific posters, Nabsys plans to highlight applications involving structural variant and copy number analysis and demonstrate how EGM could complement existing cytogenetic approaches. The collaboration with Indiana University represents another step toward establishing evidence for the technology across cancer genomics research. Nabsys was founded in 2005 and is based in Providence, Rhode Island, with its technology focused on making advanced genome structural analysis more accessible to research laboratories. By combining ultra-long DNA analysis with electronic detection and computational biology, the company aims to broaden access to detailed structural genome information. The Indiana University collaboration could provide important evidence about how the OhmX Platform performs in complex hematologic malignancies and whether EGM can add useful genomic information to existing research methods. As precision oncology increasingly relies on detailed characterization of cancer-associated genomic abnormalities, technologies capable of identifying complex structural variation may contribute to deeper understanding of disease biology and future genomic research applications.
Source: Nabsys press release
